Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
9.19
+0.26 (2.91%)
At close: Jul 3, 2025, 1:00 PM
9.16
-0.03 (-0.32%)
After-hours: Jul 3, 2025, 2:25 PM EDT
Alvotech Employees
Alvotech had 1,012 employees as of December 31, 2024. The number of employees increased by 13 or 1.30% compared to the previous year.
Employees
1,012
Change (1Y)
13
Growth (1Y)
1.30%
Revenue / Employee
$580,919
Profits / Employee
$95,400
Market Cap
2.79B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,012 | 13 | 1.30% |
| Dec 31, 2023 | 999 | 82 | 8.94% |
| Dec 31, 2022 | 917 | 133 | 16.96% |
| Dec 31, 2021 | 784 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALVO News
- 2 days ago - Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers - GlobeNewsWire
- 4 days ago - Granting of Stock Options and Vesting of Restricted Share Units - GlobeNewsWire
- 4 days ago - Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol) - GlobeNewsWire
- 9 days ago - Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility - GlobeNewsWire
- 10 days ago - Main Results of 2025 Annual and Extraordinary General Meeting - GlobeNewsWire
- 10 days ago - Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewsWire
- 10 days ago - Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewsWire
- 12 days ago - European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept) - GlobeNewsWire